GLP-1 receptor agonists improve cholesterol — but they don't all do it the same way, or to the same degree. Semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro, Zepbound) reduce triglycerides by 15-30% and modestly lower LDL.These improvements come primarily through weight loss and reduced liver fat production.
Retatrutide goes meaningfully further: its glucagon receptor activation directly commands the liver to burn stored fat. In trials, this drives 86% liver fat reduction and 35-45% triglyceride cuts. The fundamental mechanism is different and more direct.
Your liver is the factory that packages fats into cholesterol-carrying particles. When GLP-1 drugs reduce how much fat the liver has to work with — either passively through weight loss or actively through glucagon signaling with Retatrutide — fewer of those particles end up in your bloodstream.
This guide compares how semaglutide, tirzepatide, and retatrutide affect your lipid panel, with specific percentages from clinical trials and the mechanisms behind them.
At a Glance: GLP-1 Effects on Lipid Panels
| Parameter | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Triglycerides | -15% to -25% | -20% to -30% | -35% to -45% |
| LDL Cholesterol | -3% to -5% | -5% to -8% | -12% to -20% |
| HDL Cholesterol | +2% to +5% | +3% to +6% | +3% to +8% |
| Liver Fat | ~30% reduction | ~47% reduction | ~86% reduction |
| Mechanism | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
Note: Retatrutide’s glucagon component shifts the liver toward oxidation rather than lipoprotein packaging. LDL reduction includes a distinct PCSK9 degradation mechanism. Data above is from non-diabetic obesity trials (semaglutide, tirzepatide) and mixed populations (retatrutide). Lipid responses may differ in type 2 diabetes where GIP signaling is impaired.
How GLP-1 Drugs Lower Cholesterol
All three drugs reduce how much you eat, and weight loss alone improves lipids — for every 10% of body weight lost, triglycerides typically drop 15-20% and LDL drops 3-5%. But weight loss doesn't explain why retatrutide produces 86% liver fat reduction while semaglutide produces 30%:
Semaglutide: GLP-1 Only (Ozempic, Wegovy)
Semaglutide activates only GLP-1 receptors. The lipid benefits come primarily from:
- Weight loss reducing the fatty acid load the liver has to process
- Some direct hepatic effects — GLP-1 receptors in the liver reduce VLDL production (the particles that carry triglycerides)
This produces meaningful triglyceride reduction (15-25%) and modest LDL improvement (3-5%). The SELECT trial showed Ozempic/Wegovy reduced cardiovascular events by 20%. Lipid improvements were part of the overall metabolic benefit.
Tirzepatide: GLP-1 + GIP (Mounjaro, Zepbound)
Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) receptor activation. GIP receptors sit on fat cells and in the liver, providing additional metabolic signaling:
- Enhanced adipocyte metabolism — fat cells respond better to signals telling them to release or burn fat
- Improved nutrient partitioning — dietary fat gets directed toward oxidation rather than storage
- Greater weight loss — tirzepatide produces about 50% more weight loss than semaglutide at comparable doses
This translates to stronger lipid effects: 20-30% triglyceride reduction, 47% liver fat reduction in the SURPASS-3 MRI substudy. Better than semaglutide, but still primarily working through weight loss and improved fat cell signaling.
Retatrutide: GLP-1 + GIP + Glucagon
Retatrutide adds the piece that fundamentally changes the equation: glucagon receptor activation.
Glucagon is insulin's opposite. Where insulin says "store fuel," glucagon says "release and burn it." Glucagon receptors are concentrated in the liver. When activated, they directly command hepatic fat oxidation. The liver burns its stored fat for energy instead of packaging it into VLDL particles.
This is not a passive effect of eating less. It's an active signal telling the liver to mobilize fat.
The results in Phase 2 trials:
- 86% liver fat reduction — with 93% of patients on the highest dose achieving complete resolution of fatty liver (below 5% liver fat content)
- 35-45% triglyceride reduction — roughly double what semaglutide achieves
- Meaningful LDL reduction (~20% at the highest dose) — approaching low-dose statin territory. The mechanism is distinct: glucagon receptor activation promotes PCSK9 degradation in the liver, which increases LDL receptor recycling and clearance of LDL from the bloodstream. This is a direct pharmacological effect, not just a consequence of weight loss.
For lipid improvement specifically, the glucagon component is the differentiator. Semaglutide and tirzepatide improve lipids as a downstream effect of weight loss and metabolic improvement. Retatrutide directly targets the liver's fat-handling machinery.
Clinical Trial Evidence
Semaglutide Trials
| Trial | Population | Triglycerides | LDL | Other |
|---|---|---|---|---|
| SELECT | Obesity + CV disease (n=17,604) | -17% | -4% | 20% MACE reduction (major adverse cardiovascular events: heart attack, stroke, CV death) |
| STEP-1 | Obesity | -18% | -5% | — |
| STEP-2 | Obesity + T2D | -22% | -3% | — |
Consistent pattern: substantial triglyceride reduction, modest LDL improvement.
Tirzepatide Trials
| Trial | Population | Triglycerides | LDL | Liver Fat |
|---|---|---|---|---|
| SURMOUNT-1 | Obesity | -22% to -30% | -5% to -8% | — |
| SURPASS-3 MRI | T2D | -25% | — | -47% |
| SURMOUNT-5 | Obesity (vs semaglutide) | — | — | 47% more weight loss than sema |
Retatrutide Trials
| Trial | Population | Triglycerides | LDL | Liver Fat |
|---|---|---|---|---|
| Phase 2 (NEJM) | Non-diabetic obesity | ~-40% | ~-20% (12mg) | — |
| Phase 2 (T2D) | Type 2 diabetes | — | — | — |
| MASLD Substudy | Obesity + fatty liver | — | — | -86% (93% achieved resolution) |
The ~20% LDL reduction at the 12 mg dose is notable — the NEJM paper attributes this to glucagon-driven PCSK9 degradation, a direct pharmacological mechanism distinct from weight-loss-mediated lipid improvements. This approaches low-dose statin territory through a completely different pathway.
Population note: The lipid data above comes primarily from the non-diabetic obesity trial. In type 2 diabetes, where GIP signaling is impaired and metabolic baselines differ, lipid responses may vary. Separate T2D trials reported similar directional improvements but with different magnitudes.
Phase 3 trials will provide larger-scale confirmation, but the magnitude of effect — particularly on liver fat and LDL via PCSK9 — is qualitatively different from the other drugs.
What This Means for Different Lipid Profiles
For cardiovascular event reduction specifically, semaglutide has the evidence. For metabolic dysfunction where liver fat is driving risk, retatrutide's mechanism may prove more relevant — but that awaits outcome trials.
| Concern | Semaglutide | Tirzepatide | Retatrutide | Notes |
|---|---|---|---|---|
| High Triglycerides | -15% to -25% | -20% to -30% | -35% to -45% | Retatrutide's glucagon effect is most direct for severe cases (>500 mg/dL) |
| Fatty Liver (MASLD) | ~30% reduction | ~47% reduction | ~86% reduction | Glucagon targets liver fat directly, not just via weight loss |
| LDL Cholesterol | -3% to -5% | -5% to -8% | -12% to -20% | Sema/tirz modest vs statins (30-50%); retatrutide's ~20% via PCSK9 approaches low-dose statin territory |
| CV Risk Reduction | 20% MACE ↓ (SELECT) | Trial ongoing | Trial pending | Semaglutide has the outcomes data |
GLP-1 Drugs and Statins
A common question: can GLP-1 agonists like Ozempic or Mounjaro replace statins?
No. Different mechanisms, different targets.
Statins block cholesterol synthesis in the liver, forcing it to pull LDL from the bloodstream. Result: 30-50% LDL reduction. Statins are the primary tool for LDL management.
GLP-1 drugs primarily reduce triglycerides and liver fat. Semaglutide and tirzepatide have modest LDL effects (3-8%). Retatrutide is different — its ~20% LDL reduction via glucagon-driven PCSK9 degradation approaches low-dose statin territory, though it still doesn't match moderate-to-high-dose statin efficacy.
The combination makes sense for many patients:
- Statin handles LDL (the primary driver of atherosclerotic plaque)
- GLP-1 drug handles triglycerides, weight, liver fat, and overall metabolic health
The SELECT trial enrolled patients where 70% were already on statins. Semaglutide's cardiovascular benefits were additive — on top of statin therapy, not instead of it.
Timeline: When to Expect Changes
Lipid improvements track with weight loss and metabolic adaptation:
- Weeks 4-8: Early triglyceride changes may appear
- Weeks 12-16: More substantial improvements as weight loss accumulates
- Week 24+: Lipid panel typically reflects the new metabolic state
For retatrutide specifically, the direct hepatic effects may produce faster liver fat reduction than weight loss alone would predict — but this hasn't been formally studied with serial imaging.
Key Takeaways
- All GLP-1 drugs improve lipids, with triglycerides responding most dramatically (15-45% depending on drug).
- The hierarchy for lipid effects is clear: Retatrutide > Tirzepatide > Semaglutide.
- The difference is glucagon. Semaglutide and tirzepatide improve lipids primarily through weight loss. Retatrutide directly commands the liver to burn fat — an active signal, not a passive consequence.
- For liver fat specifically, retatrutide's 86% reduction is qualitatively different from tirzepatide's 47% or semaglutide's 30%. If fatty liver or severe hypertriglyceridemia is the concern, this distinction matters.
- LDL reduction is modest for semaglutide and tirzepatide (3-8%), but retatrutide achieves ~20% at high doses through glucagon-driven PCSK9 degradation — a distinct mechanism from weight loss. Statins still reduce LDL by 30-50% and remain primary therapy, but retatrutide's LDL effect is no longer trivial.
FAQ
Do GLP-1 drugs reduce triglycerides?
Yes, substantially. Semaglutide reduces triglycerides by 15-25%, tirzepatide by 20-30%, and retatrutide by 35-45%. Triglycerides are the lipid parameter most responsive to GLP-1 therapy because these drugs reduce liver fat — and the liver is where triglyceride-rich particles are assembled.
How does retatrutide lower cholesterol differently than Ozempic or Mounjaro?
Retatrutide activates glucagon receptors in addition to GLP-1 and GIP. Glucagon directly signals the liver to oxidize stored fat rather than package it into triglyceride-carrying particles — producing 86% liver fat reduction and 35-45% triglyceride cuts, roughly double what semaglutide achieves.
For LDL specifically, retatrutide has an additional mechanism: glucagon receptor activation promotes PCSK9 degradation, which increases LDL receptor recycling on liver cells and pulls more LDL out of the bloodstream. This produced ~20% LDL reduction at the highest dose in phase 2 — approaching low-dose statin territory through a completely different pathway than statins use.
Semaglutide and tirzepatide improve lipids primarily through weight loss; retatrutide adds both direct hepatic fat burning and a pharmacological LDL-lowering mechanism.
Does Ozempic lower cholesterol?
Yes. Semaglutide reduces triglycerides by 15-22% and LDL by 3-5% in clinical trials. The triglyceride effect is more pronounced than the LDL effect. These improvements are primarily driven by weight loss and reduced liver fat production.
Does Mounjaro lower cholesterol?
Yes, and somewhat more than Ozempic. Tirzepatide reduces triglycerides by 20-30% and LDL by 5-8%. The added GIP receptor activation and greater weight loss likely explain the stronger lipid effects compared to semaglutide.
Which GLP-1 drug is best for fatty liver?
Retatrutide, by a significant margin. In Phase 2 trials, retatrutide reduced liver fat by 86%, with 93% of high-dose patients achieving complete resolution of fatty liver. Tirzepatide achieved 47% liver fat reduction, semaglutide about 30%. The difference is retatrutide's glucagon component, which directly targets hepatic fat oxidation.
Can GLP-1 drugs replace statins for cholesterol?
Not yet — though retatrutide narrows the gap. Semaglutide and tirzepatide reduce LDL by only 3-8%, while statins achieve 30-50%. Retatrutide's ~20% LDL reduction via PCSK9 degradation is more meaningful but still doesn't match moderate-dose statins.
For LDL management, statins remain primary therapy. GLP-1 drugs are better understood as complementary — they handle triglycerides, liver fat, and metabolic health while statins handle LDL. The combination is additive: in the SELECT trial, 70% of participants were already on statins, and semaglutide's cardiovascular benefits stacked on top.
Do I need to take a GLP-1 drug forever, like a statin?
For semaglutide and tirzepatide, probably yes. The STEP-1 extension study showed that people who stopped Ozempic regained about two-thirds of lost weight within a year. Metabolic improvements — including lipid changes — reversed along with it. The drugs suppress appetite. Stop the drug, appetite returns, weight returns, lipids worsen.
Retatrutide might be different. If you reduce liver fat by 86% and resolve fatty liver disease, you've addressed an underlying pathology — not just suppressed appetite. The liver wasn't broken; it was overloaded with fat. Clear the backlog via glucagon-driven oxidation, and the fat may not rapidly reaccumulate. This is especially true if you maintain even partial weight loss.
Discontinuation data for retatrutide doesn't exist yet, so this is mechanistic reasoning, not proven. But it's a meaningful distinction. Ozempic and Mounjaro improve lipids as a downstream effect of eating less. Retatrutide directly burns liver fat. One is maintaining a metabolic state; the other might be resolving a condition.
What's the difference between Ozempic and Wegovy? Mounjaro and Zepbound?
Same drugs, different doses and indications:
| Brand | Drug | Dose | Indication |
|---|---|---|---|
| Ozempic | Semaglutide | Up to 2mg | Type 2 diabetes |
| Wegovy | Semaglutide | 2.4mg | Obesity/weight loss |
| Mounjaro | Tirzepatide | Up to 15mg | Type 2 diabetes |
| Zepbound | Tirzepatide | Up to 15mg | Obesity/weight loss |
The lipid effects are the same because the active drug is the same. Wegovy and Zepbound use higher doses optimized for weight loss, which may produce somewhat greater lipid improvements than the diabetes doses — but the mechanism is identical.
Related Topics
- GLP-1 Comparison Guide — full breakdown of semaglutide vs tirzepatide vs retatrutide
- Semaglutide Guide — dosing, side effects, and results
- Tirzepatide Guide — the dual-agonist option
- Retatrutide Guide — the triple-agonist with strongest lipid effects
References
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131.
- Harrison SA, et al. Retatrutide for metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30(7):2018-2028. PMID: 38858523.
- Gastaldelli A, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI). Lancet Diabetes Endocrinol. 2025.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
Medical Disclaimer
The content in this GLP-1 protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.